Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cronos Group's Enterprise Value is €391.9 Mil.
Cronos Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €51.7 Mil. Therefore, Cronos Group's EV-to-OCF for today is 7.58.
The historical rank and industry rank for Cronos Group's EV-to-OCF or its related term are showing as below:
FRA:7CI'
s EV-to-OCF Range Over the Past 10 Years
Min: -583.57 Med: -5.17 Max: 98.42
Current: 6.7
During the past 12 years, the highest EV-to-OCF of Cronos Group was 98.42. The lowest was -583.57. And the median was -5.17.
FRA:7CI's EV-to-OCF is ranked better than 60.77% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.23
vs FRA:7CI: 6.70
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cronos Group's PE Ratio (TTM) for today is calculated as:
Cronos Group's share price for today is €2.758.
Cronos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.173.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cronos Group EV-to-OCF Related Terms
Cronos Group EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cronos Group's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cronos Group's EV-to-OCF falls into.
Cronos Group's current Enterprise Value is €391.9 Mil.
Cronos Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €51.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (FRA:7CI) has a EV-to-OCF of 7.58 as of Sep. 15, 2026. According to the industry distribution chart, Cronos Group ranks #395 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Cronos Group's EV-to-OCF too high?
Cronos Group's current EV-to-OCF is 7.58. The Drug Manufacturers industry median EV-to-OCF is 10.23. Cronos Group's value of 7.58 is 25.9% below this industry median. Based on the distribution chart, Cronos Group ranks #395 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #395 out of 1007 companies for EV-to-OCF. This puts Cronos Group in the upper half of its industry. The industry median EV-to-OCF is 10.23. Cronos Group's value of 7.58 is 25.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.23, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current EV-to-OCF of 7.58 is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current EV-to-OCF is 7.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (FRA:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.19, compared to a current price of €2.76 — trading 13.5% below its estimated fair value. The current EV-to-OCF is 7.58 and 25.9% below the Drug Manufacturers industry median of 10.23. Cronos Group's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cronos Group (FRA:7CI), the current EV-to-OCF is 7.58 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (FRA:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.76 is trading 13.5% below its estimated GF Value™ of €3.19.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for FRA:7CI:
EV-to-OCF: 7.58
GF Value™: €3.19 vs. price of €2.76 (13.5% below fair value)
Industry Position: 25.9% below the Drug Manufacturers median (#395 of 1007)
No single metric tells the full story. See the FRA:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for FRA:7CI
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CI has been successfully added to your 
